Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha joining 26 (TRAJ26) is a gene segment within the T cell receptor (TCR) alpha chain locus. The TCR is a crucial immune protein on T lymphocytes, responsible for antigen recognition via binding to peptides presented by MHC molecules. TRAJ26 belongs to the joining (J) region segments involved in V(D)J recombination, which, together with variable (V) and constant (C) segments, forms the unique antigen-binding domain of the TCR α chain. During T cell development, V and J segment recombination provides repertoire diversity. TRAJ26 encodes one such J segment but does not itself produce a standalone protein or function as a receptor; rather, it is a genetic element used during TCR assembly. Key clarification: While the T cell receptor α chain (and the complete TCR) can be a therapeutic/diagnostic target, TRAJ26 itself is not a protein, receptor, or enzyme target, but a germline-encoded DNA segment involved in gene assembly.
Null (no direct mechanisms for drugs; genetic recombination at this segment forms diversity in the TCR and is not manipulated by therapeutics)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha joining 26 (TRAJ26).